Resumen de acción 1099
Sinopharm Group Co. Ltd., junto con sus filiales, se dedica a la venta al por mayor y al por menor de productos farmacéuticos, dispositivos médicos y productos sanitarios en la República Popular China. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 5/6 |
| Dividendos | 5/6 |
Competidores de Sinopharm Group Co. Ltd.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | HK$20.55 |
| Máximo en las últimas 52 semanas | HK$23.65 |
| Mínimo de 52 semanas | HK$16.02 |
| Beta | 0.86 |
| 1Cambio en 1 mes | 1.48% |
| Variación en 3 meses | 10.72% |
| Cambio de 1 año | 3.06% |
| 3Variación en 3 años | 11.08% |
| Variación en 5 años | -21.41% |
| Variación desde la OPV | 10.96% |
Noticias y actualizaciones recientes
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Recent updates
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05Rentabilidad de los accionistas
| 1099 | HK Healthcare | Mercado HK | |
|---|---|---|---|
| 7D | 1.5% | -0.6% | 0.4% |
| 1Y | 3.1% | -23.3% | 12.0% |
Rentabilidad vs. Industria: 1099 superó a la industria Hong Kong Healthcare, que obtuvo un rendimiento del -23.3% el año pasado.
Rentabilidad vs. Mercado: 1099 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fueron del 12% el año pasado.
Volatilidad de los precios
| 1099 volatility | |
|---|---|
| 1099 Average Weekly Movement | 6.1% |
| Healthcare Industry Average Movement | 8.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Precio estable de las acciones: 1099 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 1099 (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 113,635 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., junto con sus filiales, se dedica a la venta al por mayor y al por menor de productos farmacéuticos, dispositivos médicos y productos sanitarios en la República Popular China. La empresa opera a través de cuatro segmentos: Distribución Farmacéutica, Dispositivos Médicos, Farmacia Minorista y Otros Negocios. El segmento de Distribución Farmacéutica distribuye productos farmacéuticos a hospitales, otros distribuidores, farmacias minoristas y clínicas.
Resumen de fundamentos de Sinopharm Group Co. Ltd.
| Estadísticas fundamentales de 1099 | |
|---|---|
| Capitalización bursátil | HK$64.13b |
| Beneficios(TTM) | HK$9.30b |
| Ingresos (TTM) | HK$634.51b |
6.9x
Ratio precio-beneficio (PE)0.1x
Ratio precio-ventas (PS)¿Está 1099 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 1099 | |
|---|---|
| Ingresos | CN¥590.35b |
| Coste de los ingresos | CN¥543.16b |
| Beneficio bruto | CN¥47.18b |
| Otros gastos | CN¥38.53b |
| Beneficios | CN¥8.65b |
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.77 |
| Margen bruto | 7.99% |
| Margen de beneficio neto | 1.47% |
| Ratio deuda/patrimonio | 78.1% |
¿Cómo se ha desempeñado 1099 a largo plazo?
Ver rendimiento histórico y comparativa